Drug
Suzetrigine
Suzetrigine: highest development phase Post-Market, developed by Vertex Pharmaceuticals. 5 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Vertex Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Suzetrigine NCT07538570 | Post-Market | Pain |
| Suzetrigine NCT07624526 | Post-Market | Knee Arthritis |
| Suzetrigine NCT06628908 | Phase 3 | Diabetic Peripheral Neuropathic Pain |
| Suzetrigine NCT06696443 | Phase 3 | Diabetic Peripheral Neuropathic Pain |
| Suzetrigine NCT07378865 | Phase 1 | Pain |
Latest
No recent events.
Follow Suzetrigine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.